Detail of "146-22-5"

CAS Number:
146-22-5
Name:
1,3-Dihydro-7-nitro-5-phenyl-2H-1,4-benzodiazepin-2-one
Superlist Name:
Nitrazepam
Molecular Structure:
Formula:
C₁₅H₁₁N₃O₃
Molecular Weight:
281.29
Synonyms:
1,3-Dihydro-7-nitro-5-phenyl-2H-1,4-benzodiazepine-2-one;7-Nitro-5-phenyl-2,3-dihydro-1H-1,4-benzodiazepin-2-one;Benzalin;Calsmin;Dormicum;Dormicum (anticonvulsant);Dormin 5;Eatan;Epibenzalin;Epinelbon;Eunoctin;Hipnax;Hipsal;Imeson;Insomin;Ipersed;LA 1;Megadon;Mogadan;Mogadon;Mogadone;N-Desmethylnimetazepam;NSC 58775;Nelbon;Neozepam;Neuchlonic;Nipam;Nitrados;Nitravet;Nitrazepam;Nitrenpax;Nitrosun;Noctesed;Paxisyn;Pelson;Radedorm;Relact;Remnos;Ro 4-5360;Ro 5-3059;Somitran;Somnased;Somnibel;Somnite;Sonebon;Sonnolin;Surem;Unisomnia;Xiaoxipan;2H-1,4-Benzodiazepin-2-one,1,3-dihydro-7-nitro-5-phenyl-;
EINECS:
205-665-2
Density:
1.4 g/cm³
Melting Point:
226-229 ºC
Boiling Point:
497 ºC at 760 mmHg
Flash Point:
254.4 ºC
Solubility:
76.9 mg/L 25 °C in water
Appearance:
Pink Solid
Hazard Symbols:
Risk Codes:
R22
Safety:
Poison by intraperitoneal and intravenous routes. Moderately toxic by ingestion. Experimental reproductive effects. Mutation data reported. An anticonvulsant and hypnotic agent. When heated to decomposition it emits toxic fumes of NO_x. See also DIAZEPAM. Details

Please post your buying leads,so that our qualified suppliers will soon contact you!
*Required Fields

Changes in reaction time and drug plasma concentrations after nitrazepam and glutethimide: Changes in reaction time and drug plasma concentrations after nitrazepam and glutethimide. Curry, S. H.; Whelpton, R.; Scott, D. F. (Dep. Pharmacol. Therap., London Hosp. Med. Coll., London, Engl.). Br. J. Clin. Pharmacol., 4(2), 109-14 (English) 1977. CODEN: BCPHBM. DOCUMENT TYPE: Journal CA Section: 1 (Pharmacodynamics) The effects of nitrazepam (I) [146-22-5], glutethimide [77-21-4] and placebo were assessed in a double-blind cross-over study with five healthy human subjects, using reaction time, and relating changes to drug concns. in the plasma. After glutethimide in all five subjects, and after I in four subjects, larger doses led to higher concns. in plasma and to greater changes in reaction time; one subject displayed the higher I concns. and the greater effect following the smaller dose. The relationship between change in reaction time and concn. appeared to be mainly a within-subject dose-effect relationship, with the peak concn. in plasma as the dose and the area under the reaction time curve as the effect.

Plasma nitrazepam concentrations after an acute intake and their correlation to sedation and serum growth hormone levels: Plasma nitrazepam concentrations after an acute intake and their correlation to sedation and serum growth hormone levels. Kangas, L.; Kanto, J.; Syvalahti, E. (Inst. Biomed., Univ. Turku, Turku, Finland). Acta Pharmacol. Toxicol., 41(1), 65-73 (English) 1977. CODEN: APTOA6. DOCUMENT TYPE: Journal CA Section: 1 (Pharmacodynamics) In healthy volunteers after an acute peroral administration of nitrazepam (I) [146-22-5] (5 and 10 mg), the peak plasma concn. was achieved at 120 min (46.9 ng/mL after 5 mg of I) and at 180 min (82.8 ng/mL) after the dose of 10 mg. The half-life of I in plasma ranged from 16.5 to 48.3 (mean 28.8) h. A significant pos. correlation was seen between the subjective sedative effects and the magnitude of the peak I concn. in plasma. This drug effect was highly significant when the plasma levels of I were rising. The subjective sedative effects were more prominent after 10 mg than after 5 mg dose of I. The plasma I concn. was not significantly correlated with the subjective sedative effect the next morning, 12 h after the drug intake. Serum growth hormone [9002-72-6] levels rose significantly during the study both after 5 mg and 10 mg I doses (peak levels 16.3 and 12.7 ng/mL) and were significantly higher than after placebo administration (37 ng/mL).